SUPPORTING INFORMATION

Octreotide-Mediated Tumor-Targeted Drug Delivery via a Cleavable Doxorubicin–Peptide Conjugate

Marco Lelle[a], Stefka Kaloyanova[a], Christoph Freidel[a], Marily Theodoropoulou[b], Michael Musheev[c], Christof Niehrs[c,d], Günter Stalla[b] and Kalina Peneva[a,e]*

a Max Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany

b Max Planck Institute for Psychiatry, Kraepelinstraße 2, 80804 Munich, Germany

c Institute of Molecular Biology, Ackermannweg 4, 55128 Mainz, Germany

d Division of Molecular Embryology, DKFZ-ZMBH Alliance, 69120 Heidelberg, Germany

e Institute of Organic Chemistry and Macromolecular Chemistry, Friedrich Schiller University Jena, Lessingstrasse 8, 07743 Jena

*To whom correspondence should be addressed. Phone: +496131379136;

E-mail: peneva@mpip-mainz.mpg.de

Synthesized compounds:



2



4



6



7



9



two isomers of **12**

^{1}H NMR spectrum of compound **2** recorded in DMSO-d^{6} at 300 MHz



^{13}C NMR spectrum of compound **2** recorded in DMSO-d^{6} at 75 MHz



^{1}H NMR spectrum of compound **4** recorded in DMSO-d^{6} at 300 MHz



^{13}C NMR spectrum of compound **4** recorded in DMSO-d^{6} at 75 MHz



^{1}H NMR spectrum of compound **6** recorded in DMSO-d^{6} at 300 MHz



^{13}C NMR spectrum of compound **6** recorded in DMSO-d^{6} at 75 MHz



^{1}H NMR spectrum of compound **7** recorded in DMSO-d^{6} at 300 MHz



^{13}C NMR spectrum of compound **7** recorded in DMSO-d^{6} at 75 MHz



^{1}H NMR spectrum of compound **9** recorded in DMSO-d^{6} at 850 MHz



MALDI-TOF mass spectrum of compound **12** (matrix: α-cyano-4-hydroxycinnamic acid)



HPLC chromatogram of a sample from the reaction mixture (after 5 minutes) of the doxorubicin-octreotide conjugate formation, which is showing the two narrow peaks for both isomers of the hybrid **12** as well as the peak for the unreacted doxorubicin derivative **9**.



Cytotoxic effect of Dox-Oct conjugate (**12**) on A549 adenocarcinomic human alveolar basal epithelial cells (72 h after incubation with the compound) as determined by the CellTiter-Glo® luminescent cell viability assay.